AJ1-10502 / Ajax Therap - LARVOL DELTA

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs) (ASH 2022) - "Type I JAK inhibition (JAKi) represents a mainstay therapy for myelofibrosis and hydroxyurea-resistant high-risk polycythemia vera. Current type I JAKi, including ruxolitinib (RUX) and fedratinib, improve symptoms and outcomes in MPNs; however, JAK2VF allele burden remains essentially unchanged, and efficacy wanes over time...Kinome selectivity profiling of AJ1-10502 revealed potent JAK2 selectivity with minimal kinase cross-reactivity compared to CHZ868, including among other JAK family tyrosine kinases (Figure 1A)...Most importantly, AJ1-10502 results in superior reductions in PB and BM mutant cell fraction in vivo not observed with type I JAKi. These data demonstrate the preclinical utility of type II JAKi with AJ1-10502 and inform a path to clinical development of type II JAKi for MPN patients."

Clinical • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Transplantation • JAK2

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting (Businesswire) - "Ajax Therapeutics... announced the presentation of preclinical data on the company’s next generation Type II JAK2 inhibitor, AJ1-10502, at a poster session held today at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans....The poster...highlights the improved efficacy and disease modifying features of Ajax’s Type II JAK2 inhibitor, AJ1-10502, when compared to the investigational, first generation Type II inhibitor, CHZ868, and the approved market-leading Type I inhibitor, ruxolitinib, in two different mouse models of MPNs."

Preclinical • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology

Ajax Therapeutics Announces Oral and Poster Presentations on Next‑Generation JAK2 Inhibitors at American Society of Hematology Annual Meeting (Businesswire) - "Ajax Therapeutics...announced two abstracts have been accepted for oral and poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022 in New Orleans. The presentations highlight preclinical data on Ajax’s next-generation JAK2 inhibitors for the treatment of MPNs."

Preclinical • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology

Ajax Therapeutics Announces Oral and Poster Presentations on Next‑Generation JAK2 Inhibitors at American Society of Hematology Annual Meeting (Businesswire) - "Ajax Therapeutics, Inc...today announced two abstracts have been accepted for oral and poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022 in New Orleans. The presentations highlight preclinical data on Ajax’s next-generation JAK2 inhibitors for the treatment of MPNs."

Preclinical • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology